Which adverse effects are included in the boxed warning for montelukast?

Montelukast, a medication commonly used for managing asthma and allergic rhinitis, carries a boxed warning due to concerns about serious mental health effects, specifically suicidal ideation. This warning highlights the potential risk of mood changes, including symptoms of depression and suicidal thoughts, which has been observed in some patients. The boxed warning serves to inform healthcare providers and patients about the importance of monitoring for these symptoms, particularly in pediatric and adolescent populations, who may be more vulnerable.

While other side effects such as rash, bone pain, and nervousness can occur with montelukast use, they do not carry the same level of concern or specific warning related to mental health that suicidal ideation does. The inclusion of suicidal ideation in the boxed warning is a crucial point for patient safety, emphasizing the need for awareness and prompt intervention if these symptoms arise.